Latest News

To date, there are 57 Phase 2 and 23 Phase 3 ongoing clinical trials to test potential Alzheimer’s medications. Read the full article here

By 2029, more than 20 percent of people in the United States will be over the age of 65. That’s why the race to find effective treatments for Alzheimer’s disease feels urgent. Read the full article here.

Dr. David Morgan and George Vradenburg penned an op-ed in The Hill about the need for the healthcare system to prepare for innovative Alzheimer's treatments.

George Vradenburg appeared on NPR's The Diane Rehm Show to discuss the cost of Alzheimer's care and its impact on families. Read the full transcript.

According to a recent analysis by ResearchersAgainstAlzheimer's, 17 drugs are on pace to launch in the next five years.

Read the Press Release

"Alzheimer's research gets a boost," by Dr. David Morgan, CEO of the University of South Florida's Health Byrd Alzheimer's Institute.

Last month, George Vradenburg and ResearchersAgainstAlzheimer’s held an expert webinar exploring what is needed to find a cure for this cruel disease.

"Inside Report from Washington and G7/8: Focus on Resources, Clinical Trials, and Regulatory Change"

"Investment in research failing to keep pace with scope of Alzheimer’s" by Dr. David Morgan, CEO of USF Health Byrd Alzheimer’s Institute in Tampa, and lead representative of ResearchersAgainstAlzheimer’s.

Click here to read the letter to the editor from Dr. John Trojanowski, Director of the National Institute on Aging-funded Alzheimer's Disease Core Center in the Perelman School of Medicine at the University of Pennsylvania, and Founding Member of ResearchersAgainstAlzheimer's published on January 5, 2014 in the Scranton-Times Tribune. He argues that "the United States must take the lead in this concerted effort against Alzheimer's".